<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02592473</url>
  </required_header>
  <id_info>
    <org_study_id>18236</org_study_id>
    <nct_id>NCT02592473</nct_id>
  </id_info>
  <brief_title>Prostate Artery Embolization (PAE) for Treatment of Benign Prostatic Hyperplasia</brief_title>
  <official_title>Prostate Artery Embolization Safety and Efficacy: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Siemens Medical Solutions</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this project is to evaluate the safety, efficacy, and feasibility of
      performing prostatic artery embolization (PAE) using endovascular techniques and particle
      embolics in men suffering from lower urinary tract symptoms (LUTS) due to benign prostatic
      hyperplasia (BPH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This pilot study is a prospective, non-randomized clinical trial assessing the safety and
      feasibility of prostatic artery embolization. Fifty adult male subjects will be enrolled and
      treated in this study. Patients who provide informed consent and are deemed eligible for
      participation will undergo prostatic artery embolization in the Interventional Radiology
      department at the University of Virginia. After performing an angiogram to identify the
      prostatic arteries, tiny particles known as Embozene Microspheres will be injected into the
      prostatic artery. Injecting these particles into the prostatic artery will slow blood flow to
      the prostate and thus shrinking the size of the prostate. By shrinking the size of the
      prostate, it is hopeful that it will provide relief of lower urinary tract symptoms due to
      BPH. Subjects will be followed for 2 years as part of their participation in this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical improvement in Lower Urinary Tract Symptoms (LUTS)</measure>
    <time_frame>12 months</time_frame>
    <description>QMax (peak urinary flow rate) assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence or absence of ischemic complications to the bladder, rectum, or other pelvic structures</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical improvement in Lower Urinary Tract Symptoms (LUTS)</measure>
    <time_frame>24 months</time_frame>
    <description>QMax assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Presence or absence of ischemic complications to the bladder, rectum, or other pelvic structures</measure>
    <time_frame>24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical improvement in Lower Urinary Tract Symptoms (LUTS)</measure>
    <time_frame>12 months</time_frame>
    <description>IPSS (International Prostate Symptom Score)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical improvement in Lower Urinary Tract Symptoms (LUTS)</measure>
    <time_frame>24 months</time_frame>
    <description>IPSS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical improvement in Lower Urinary Tract Symptoms (LUTS)</measure>
    <time_frame>12 months</time_frame>
    <description>QoL(quality of life question)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical improvement in Lower Urinary Tract Symptoms (LUTS)</measure>
    <time_frame>24 months</time_frame>
    <description>QoL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical improvement in Lower Urinary Tract Symptoms (LUTS)</measure>
    <time_frame>24 months</time_frame>
    <description>QMax</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Urine flow rate as measured by QMax</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine flow rate as measured by QMax</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-void residual measured in ml/cc</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-void residual measured in ml/cc</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UCLA-PCI-SF (University of California, Los Angeles Prostate Cancer Index Short Form) score</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UCLA-PCI-SF score</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Prostatic Hyperplasia</condition>
  <condition>Benign Prostatic Hyperplasia (BPH)</condition>
  <condition>Prostatism</condition>
  <condition>Lower Urinary Tract Symptoms (LUTS)</condition>
  <condition>Prostatic Hypertrophy</condition>
  <condition>Hyperplasia</condition>
  <condition>Male Urogenital Diseases</condition>
  <condition>Genital Diseases, Male</condition>
  <arm_group>
    <arm_group_label>Embozene Microspheres</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Embozene Microspheres are spherical particles consisting of a hydrogel core and a poly nanocoat that will be used during study procedure, Prostatic Artery Embolization (PAE) to reduce or eliminate bloodflow to the prostate.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Embozene Microspheres</intervention_name>
    <description>Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.</description>
    <arm_group_label>Embozene Microspheres</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between ages 45-80 years

          -  Diagnosis of Lower Urinary Tract Symptoms from Benign Prostatic Hypertrophy for a
             minimum of 6 months

          -  IPSS score at initial evaluation should be greater than 7, and uroflowmetry (Qmax) of
             &lt;12mL/s (milliliters per second) .

          -  All prostate volumes will be&gt; 50gm and &lt; 400gm

        Exclusion Criteria:

          -  Patients with urinary tract infections (&gt; 2/year), prostatitis, or interstitial
             cystitis

          -  Cases of biopsy proven prostate cancer or urethral cancer.

          -  Patients on long-term narcotic analgesia, androgen therapy, or GNRH
             (gonadotropin-releasing hormone) analogue therapy within 2 months of study.

          -  Patients who are classified as New York Heart Association Class III (Moderate), or
             higher.

          -  Patients with history of prior pelvic irradiation.

          -  Hypersensitivity reactions to contrast material not manageable with prophylaxis.

          -  Patients with serum creatinine values &gt;1.7mg/dl or glomerular filtration rates less
             than 50.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ziv J Haskal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Radiology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amelia R Adelsperger, MS</last_name>
    <phone>434-297-5682</phone>
    <email>ara9f@virginia.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Brigitte J Kelly, BSN RN CCRC</last_name>
    <phone>434-297-7136</phone>
    <email>bjk3c@virginia.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Virginia Health Systems</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amelia R Adelsperger, MS</last_name>
      <phone>434-297-5682</phone>
      <email>ara9f@virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Brigitte J Kelly, BSN RN CCRC</last_name>
      <phone>434-297-7136</phone>
      <email>bjk3c@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Ziv J Haskal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 26, 2015</study_first_submitted>
  <study_first_submitted_qc>October 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2015</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Ziv Haskal, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Prostate Artery Embolization (PAE)</keyword>
  <keyword>Benign Prostatic Hyperplasia (BPH)</keyword>
  <keyword>Lower Urinary Tract Symptoms (LUTS)</keyword>
  <keyword>BPH</keyword>
  <keyword>PAE</keyword>
  <keyword>LUTS</keyword>
  <keyword>Prostatic Artery Embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
    <mesh_term>Genital Diseases, Male</mesh_term>
    <mesh_term>Prostatism</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

